Published in Clin Cases Miner Bone Metab on September 01, 2009
Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells. Stem Cell Res (2013) 0.78
Modulating testosterone pathway: a new strategy to tackle male skin aging? Clin Interv Aging (2012) 0.75
Preservation and promotion of bone formation in the mandible as a response to a novel calcium-phosphate based biomaterial in mineral deficiency induced low bone mass male versus female rats. J Biomed Mater Res A (2016) 0.75
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 7.14
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev (2000) 2.94
Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br (1998) 2.82
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab (2000) 2.68
Alcohol intake as a risk factor for fracture. Osteoporos Int (2004) 2.34
Androgens and bone. Endocr Rev (2004) 2.06
Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res (2006) 1.91
Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest (2003) 1.84
Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab (1997) 1.72
Nuclear-receptor interactions on DNA-response elements. Trends Biochem Sci (2001) 1.60
The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem (1989) 1.58
Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA (2008) 1.57
Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab (2001) 1.57
Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol (2004) 1.56
Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int (1999) 1.50
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab (2002) 1.40
International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Osteoporos Int (1999) 1.39
Racial differences in bone mineral density in older men. J Bone Miner Res (2003) 1.30
Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis (1987) 1.21
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom (2002) 1.20
Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol (2002) 1.19
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab (1987) 1.04
Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.04
Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res (2004) 1.02
Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol (2002) 1.02
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol (2008) 1.00
New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab (2004) 0.97
Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab (1993) 0.97
Osteoporosis in men. Best Pract Res Clin Endocrinol Metab (2008) 0.95
Androgen receptor functions in male and female physiology. J Steroid Biochem Mol Biol (2008) 0.91
Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl (2002) 0.90
Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom (2002) 0.88
Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) (2001) 0.81
Formulation of a reservoir-type testosterone transdermal delivery system. Int J Pharm (2001) 0.80
Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med (2006) 1.68
A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab (2004) 1.25
Multiple endocrine neoplasia type 2. Orphanet J Rare Dis (2006) 1.23
Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol (2002) 1.21
Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet (2011) 1.20
Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg (2007) 1.10
Multiple endocrine neoplasia type 1. Orphanet J Rare Dis (2006) 1.08
Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone (2007) 1.07
Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res (2009) 1.05
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol (2010) 1.04
ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer (2005) 0.97
Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg (2006) 0.96
Polyostotic form of fibrous dysplasia in a 13 years old Colombian girl showing clinical and biochemical response to neridronate intravenous therapy. Clin Cases Miner Bone Metab (2009) 0.92
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Curr Med Res Opin (2008) 0.83
The regulatory network menin-microRNA 26a as a possible target for RNA-based therapy of bone diseases. Nucleic Acid Ther (2012) 0.83
Phytoestrogens: food or drug? Clin Cases Miner Bone Metab (2007) 0.82
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed) (2011) 0.81
Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. Cancer Genet Cytogenet (2009) 0.79
What is the relationship between Paget's disease of bone and hyperparathyroidism? J Bone Miner Res (2006) 0.79
Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit (2003) 0.79
Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent. Clin Cases Miner Bone Metab (2010) 0.78
Infiltrating giant cell tumor in a case of Paget's disease of bone. Arch Osteoporos (2009) 0.78
Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus. Clin Cases Miner Bone Metab (2010) 0.78
The bone care nurse project. Clin Cases Miner Bone Metab (2011) 0.77
Calcium bioavailability from a calcium-rich mineral water, with some observations on method. J Clin Gastroenterol (2004) 0.77
A novel polymorphism at the GNAS1 gene associated with low circulating calcium levels. Clin Cases Miner Bone Metab (2007) 0.77
Surgical approach in hereditary hyperparathyroidism. Endocr J (2009) 0.77
Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? J Clin Endocrinol Metab (2009) 0.76
Osteonecrosis in genetic disorders. Clin Cases Miner Bone Metab (2007) 0.76
Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women. Clin Cases Miner Bone Metab (2009) 0.76
LRP5 gene polymorphism and cortical bone. Aging Clin Exp Res (2010) 0.75
The role of osteoprotegerin (OPG) and estrogen receptor (ER-α) gene polymorphisms in rheumatoid arthritis. Clin Cases Miner Bone Metab (2007) 0.75
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. Clin Cases Miner Bone Metab (2011) 0.75
Genetics of primary hyperparathyroidism. Urol Int (2004) 0.75